All News
2022 ACR/EULAR Classification Criteria for GCA
Dr. Michael Putman discusses interesting take-home messages from the Vasculitis Investigators Meeting at ACR22 Convergence regarding the 2022 ACR/EULAR Classification Criteria for GCA.
https://t.co/FL9FGhWcxB https://t.co/JKi7Nn4O2O
Links:
Dr. John Cush RheumNow ( View Tweet)
Avoid Abatacept in RA patients with a history of cancer?
Dr. Richard Conway ( @RichardPAConway ) discusses abstracts #0267 and #0255 presented at #ACR22.
https://t.co/1lC33XlBt7 https://t.co/ttUQaTVF43
Links:
Dr. John Cush RheumNow ( View Tweet)
Anifrolumab shows long-term promise in patients with lupus
Researchers report positive results from the first placebo-controlled long-term trial of anifrolumab—a human monoclonal antibody that targets the type I IFN receptor—in patients with lupus.
https://t.co/IlgEUKkMOv https://t.co/kpSt61d5Qx
Links:
Dr. John Cush RheumNow ( View Tweet)
Effect of voclosporin in class V lupus nephritis
Dr. Yusof ( @Yuz6Yusof) discusses abstract 0355 presented at #ACR22. Abstract 0355: Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study
https://t.co/sH04dhBskS https://t.co/mUOrJKdYBF
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR22 - Day 1
https://t.co/GlEhTnKXm7 https://t.co/JFyMSpjFq3
Links:
Dr. John Cush RheumNow ( View Tweet)
JAK vs TNF inhibitor Infections in RA
Dr. David Liew ( @drdavidliew) discusses abstract 0302 at #ACR22 Convergence. Abstract 0302: Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis
https://t.co/ipD5ON7BJ7 https://t.co/rRD5wqHhFk
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR22 Appraisal, Praise & Critique
Dr. Cush talks ACR22, the highs and the lows.
https://t.co/1SVr2LLOcG https://t.co/PqcMix7O1f
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective review of 265 ILD pts - 9.8% were ANCA positive (PR3, MPO). ANCA- oft called IPF. ANCA+ CTD-ILD and 65% evolved into AAV (29% AAV follwed ILD Dx). No lung diff betw Pos v Neg pts, but ANCA+ had more drugs, hosp. #ACR22 https://t.co/X6UfiawfmW https://t.co/BZpTsjYAFW
Links:
Dr. John Cush RheumNow ( View Tweet)
Breakthrough COVID infection in SLE during Omicron era
Dr. Yusof ( @Yuz6Yusof) talks with Dr. Amit Saxena about abstract #2081 at #ACR22
Abstract 2081: COVID-19 Infections, Morbidity, and Seroreactivity in SLE Patients....
https://t.co/0OFcHK2PLj https://t.co/2ULOfSZUqU
Links:
Dr. John Cush RheumNow ( View Tweet)
Opioids and Health Care Utilization in PsA and AS
Dr Aurelie Najm ( @AurelieRheumo) discusses Abstract 0402 presented at #ACR22. Abstract 0402: Opioid Use and Healthcare Utilization in Adults with PsA and AS
https://t.co/trruZGyIVf https://t.co/8kj9vpKPlD
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Ted Mikuls has authored a Clinical practive review of Gout in this weeks New England Journal of Medicine - Congrats Ted! https://t.co/8MuC6upkOT https://t.co/zO4nZbWQ5A
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective review of 185 hospitalized AOSD pts (incidence 0.16 - 0.21/100K); Mean age 47 (70% female), mean ESR 55, CRP 12.26, ferritin 7141 WBC 12.15, anemia 23%. 24% ICU care & overall mortality was 3.2%. Ab#0829 #ACR22 https://t.co/eDRY4b3GAg https://t.co/3pt0ZH5QQH
Links:
Dr. John Cush RheumNow ( View Tweet)
Best of PsA on Day 1
Dr. Rachel Tate ( @uptoTate) discusses the best PSA data presented 11/12 at #ACR22
https://t.co/i93CX7wic3 https://t.co/dQDOcIsu1P
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR22 - Day 2 Part III
RheumNow and its reporters review abstracts presented on Day 2 of #ACR22.
https://t.co/uUiX7s5Ajf https://t.co/0E5KSpOyyL
Links:
Dr. John Cush RheumNow ( View Tweet)
Survival and Mortality in RA: time to move away from “one-size fits all”?
Dr. Aurelie Najm ( @AurelieRheumo ) reviews Abstract #0246 at #ACR22.
https://t.co/O4dNzCZmmd https://t.co/cWUXEpduID
Links:
Dr. John Cush RheumNow ( View Tweet)
Exciting Data for SLE: Plenaries from #ACR22
Dr. Michael Putman ( @EBRheum ) shares SLE updates shared at #ACR22.
https://t.co/34HAvc2S8F https://t.co/xINo52fF2O
Links:
Dr. John Cush RheumNow ( View Tweet)
Can computers tell the difference between RA & PsA?
Dr. David Liew ( @drdavidliew) discusses Abstract 0242 presented at #ACR22. Abstract 0242: Neural Networks for Distinguishing RA from PsA by Using Magnetic Resonance Imaging
https://t.co/ZL5TYIdT6Q https://t.co/tZWIAl0rb0
Links:
Dr. John Cush RheumNow ( View Tweet)
Upadacitinib vs Adalimumab in PsA using RAPID3
Dr. Catherine Sims ( @DrCassySims) discusses abstract 0192 presented at #ACR22. 0192: Upadacitinib versus Adalimumab on Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with PsA,
https://t.co/nRjgM45GdO https://t.co/MDqpW7ACXa
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR22 Rheumatology Roundup w/ Drs. Kavanaugh & Cush
#1044 Combo Rx SpA
#0533 CCP spit
#1604 StopRA
#2251 Tofa & RA ILD
#0420 NSAID SpA
#002 CA in IIM
#0113 BTK Sjogrens
#L05 Prolia EOA
#0526 Pexivas
#1106 TCZ PMR
Video: https://t.co/JG3spEsYDD
Podcast: https://t.co/nbmeiGo2yt https://t.co/E7RDPTFsaS
Dr. John Cush RheumNow ( View Tweet)
Urinary Biomarkers in Lupus
Dr.Cush interviews Dr. Fava about Abstract 536 at #ACR22. Abstract 0536: Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria
https://t.co/3IfPdTMufb https://t.co/XVECG9mJri
Links:
Dr. John Cush RheumNow ( View Tweet)